Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Share-based Compensation (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Share-based Compensation for 11 consecutive years, with $254398.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 48.62% year-over-year to $254398.0, compared with a TTM value of $825968.0 through Sep 2025, up 21.69%, and an annual FY2024 reading of $656593.0, down 13.03% over the prior year.
  • Share-based Compensation was $254398.0 for Q3 2025 at Kiora Pharmaceuticals, down from $262774.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $264864.0 in Q3 2023 and bottomed at $135941.0 in Q1 2023.
  • Average Share-based Compensation over 5 years is $195982.6, with a median of $178893.5 recorded in 2023.
  • The sharpest move saw Share-based Compensation tumbled 37.04% in 2023, then soared 75.42% in 2025.
  • Year by year, Share-based Compensation stood at $213169.0 in 2021, then rose by 1.29% to $215921.0 in 2022, then decreased by 15.55% to $182344.0 in 2023, then decreased by 12.16% to $160180.0 in 2024, then soared by 58.82% to $254398.0 in 2025.
  • Business Quant data shows Share-based Compensation for KPRX at $254398.0 in Q3 2025, $262774.0 in Q2 2025, and $148616.0 in Q1 2025.